Cell therapy weekly: New company born out of collaboration between ElevateBio and Boston Children’s hospital will develop iPSC-derived CAR- T cells with enhanced anti-tumor activity
This week: New company born out of collaboration between ElevateBio and Boston Children’s hospital will develop induced pluripotent stem cell (iPSC)-derived CAR-T cells with enhanced anti-tumor activity, Eyestem secure US$6.4 million in series A funding to progress allogeneic cell therapy for dry age-related macular degeneration to clinical trials and Charles River becomes first North American contract development and manufacturing organization (CDMO) to receive EMA approval to commercially manufacture and ship allogeneic cell therapy products.
The news highlights:
-
-
-
-
- New company born out of collaboration between ElevateBio and Boston Children’s hospital will develop iPSC-derived CAR-T cells with enhanced anti-tumor activity
- Eyestem secure US$6.4 million in series A funding to progress allogeneic cell therapy for dry age-related macular degeneration to clinical trials
- Charles River becomes first North American CDMO to receive EMA approval to commercially manufacture and ship allogeneic cell therapy products
-
-
-
Company born out of collaboration between ElevateBio and Boston Children’s hospital will develop iPSC-derived CAR-T cells with enhanced anti-tumor activity
ElevateBio, (MA, USA) a technology-driven company committed to powering the development of transformative cell and gene therapies, has formed a new startup, co-founded by Dean of Harvard Medical School (MA, USA), George Daley and Boston Children’s Hospital (MA, USA). The yet unnamed company will develop allogeneic immune cell therapies based upon a novel method of generating functionally mature CAR-T cells from iPSCs.
David Hallal, Chairman and Chief Executive Officer of ElevateBio stated “This exciting new company is the first from our collaboration with Boston Children’s Hospital and is a prime example of how our integrated ecosystem – our iPSC cell lines and process development capabilities, our gene editing technology, our CAR and TCR constructs, and our scale-up manufacturing capabilities – creates the perfect foundation needed to turn these scientific breakthroughs into transformational medicines.”
Eyestem secure US$6.4 million in series A funding to progress allogeneic cell therapy for dry age-related macular degeneration to clinical trials
Eyestem (Bengaluru, India), a cell therapy biotech start-up, has secured US$6.4 million in series A funding to progress their patented allogeneic cell therapy product for dry age-related macular degeneration, Eyecyte-RPE, to clinical trials. Eyestem plans to file for a first in human trial for the product within one year in consultation with Central Drugs Standard Control Organisation (New Delhi, India) and the US FDA. The funding was led by Biological E Ltd (Hyderabad, India), Alkem Laboratories (Mumbai, India) and Natco Pharma (Hyderabad, India).
Jogin Desai, founder and Chief Executive Officer of Eyestem stated “We started Eyestem with the sole purpose of being able to create cell therapy products at scale for diseases that devastate a large number of people in India and the world. The support of major Indian pharma companies who share our vision endorses our strategy of developing affordable innovation for patients worldwide.”
Charles River becomes first North American CDMO to receive EMA approval to commercially manufacture and ship allogeneic cell therapy products
Charles River Laboratories (MA, USA) has been awarded a commercial Good Manufacturing Practice (GMP) license from the European Medicines Agency (EMA; Amsterdam, Netherlands), to commercially manufacture and ship allogeneic cell therapy products for European Union distribution. This approval makes Charles River Laboratories the first North American CDMO to receive EMA approval for commercial production of allogeneic cell therapy products.
Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer of Charles River stated “We are incredibly proud that our Memphis facility has received EMA approval to commercially manufacture an allogeneic cell therapy. We are looking forward to continuing close partnerships with our clients and supporting future commercial projects, bringing these potentially curative therapies to patients, sooner.”
You might also like:
